BeOne Medicines Ltd. – Sponsored ADR $ONC Holdings Boosted by WESPAC Advisors SoCal LLC

WESPAC Advisors SoCal LLC grew its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 66.6% in the 1st quarter, Holdings Channel reports. The firm owned 4,925 shares of the company’s stock after acquiring an additional 1,968 shares during the quarter. WESPAC Advisors SoCal LLC’s holdings in BeOne Medicines were worth $1,463,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. EFG International AG bought a new position in BeOne Medicines during the 4th quarter worth $25,000. Leonteq Securities AG acquired a new position in shares of BeOne Medicines during the fourth quarter valued at $35,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the second quarter worth about $35,000. CWM LLC increased its holdings in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines in the 4th quarter worth about $61,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BeOne Medicines

In other news, SVP Chan Henry Lee sold 871 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $270.42, for a total value of $235,535.82. Following the sale, the senior vice president owned 160 shares of the company’s stock, valued at approximately $43,267.20. The trade was a 84.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 4,940 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40. Following the completion of the sale, the chief executive officer owned 1,120 shares of the company’s stock, valued at approximately $303,027.20. This trade represents a 81.52% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 21,466 shares of company stock worth $5,768,875 in the last quarter. Company insiders own 6.19% of the company’s stock.

BeOne Medicines Price Performance

NASDAQ ONC opened at $270.15 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $239.25 and a 12 month high of $385.22. The firm has a market capitalization of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49. The company’s 50 day simple moving average is $295.32 and its 200 day simple moving average is $312.15. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on ONC. Royal Bank Of Canada boosted their target price on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Barclays raised their target price on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Wells Fargo & Company started coverage on BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Finally, Guggenheim increased their price target on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.